Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer
2022 · Nature Cancer · 96 citations
https://doi.org/10.1038/s43018-022-00358-1
L
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
65
Papers
2.2K
Citations
25
h-index
36
i10-index
Liang Hu is an academic researcher from Shanghai University of Traditional Chinese Medicine. The author has contributed to research in topics: Lung Cancer Research Studies & RNA modifications and cancer & Epigenetics and DNA Methylation. The author has an h-index of 25, co-authored 56 publications.
ORCID: 0000-0002-0984-9807Papers by this author
worksA20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression
2015 · Molecular Cancer · 59 citations
https://doi.org/10.1186/s12943-015-0454-6
SP6616 as a new Kv2.1 channel inhibitor efficiently promotes β-cell survival involving both PKC/Erk1/2 and CaM/PI3K/Akt signaling pathways
2016 · Cell Death and Disease · 37 citations
https://doi.org/10.1038/cddis.2016.119
Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adeno-to-squamous transdifferentiation
2023 · Signal Transduction and Targeted Therapy · 35 citations
https://doi.org/10.1038/s41392-022-01227-0
Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer
2015 · BMC Cancer · 26 citations
https://doi.org/10.1186/s12885-015-1285-y
Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer
2025 · Signal Transduction and Targeted Therapy · 3 citations
https://doi.org/10.1038/s41392-025-02382-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat